Loading…
Unicycive Therapeutics, Inc. is projected to rise to $11.08 by 2027, a +57% move from its current price of $7.07. UNCY is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $6.81 | $7.07 | $7.34 | +0.03% |
| May 30 | $6.71 | $7.07 | $7.46 | +0.07% |
| May 31 | $6.63 | $7.08 | $7.55 | +0.10% |
| Jun 1 | $6.57 | $7.08 | $7.63 | +0.13% |
| Jun 2 | $6.51 | $7.08 | $7.70 | +0.16% |
| Jun 3 | $6.46 | $7.08 | $7.76 | +0.20% |
| Jun 4 | $6.42 | $7.09 | $7.82 | +0.23% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $6.42 | $7.09 | $7.82 | +0.23% |
| Week 2 | $6.18 | $7.10 | $8.17 | +0.46% |
| Week 3 | $6.00 | $7.12 | $8.45 | +0.69% |
| Week 4 | $5.86 | $7.13 | $8.69 | +0.92% |
| Week 5 | $5.73 | $7.15 | $8.92 | +1.15% |
| Week 6 | $5.63 | $7.17 | $9.13 | +1.38% |
| Week 7 | $5.53 | $7.18 | $9.33 | +1.61% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Unicycive Therapeutics, Inc. is a clinical-stage biotechnology company that identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease.
The company was incorporated in 2016 and is headquartered in Mountain View, California. It is categorized in the Healthcare category.
Unicycive Therapeutics, Inc. (UNCY) is currently priced at $7.06 with a market cap of $188.5M, and it ranks 3879 by market cap. This places the company among smaller-cap biotechnology names in the market landscape.
The price outlook is constructive over the medium to long term, with a year-by-year forecast showing rising averages and sizable upside later in the horizon. The forecast spans from 2026 through 2050, with the 2027 average at $10.95, rising to $85.18 as the 2050 average, and a 2050 max of $181.73. Max ROI reaches 1106.6% in 2050, with bullish sentiment prevailing in most years.
A major floor 17.3% below — a decisive break under it would weaken the trend.
Price is testing support right now (2.4% away) — a key level to hold.
The nearest ceiling, 21.1% above — a clean break opens room to run.
A major ceiling 29.7% above — clearing it would confirm fresh momentum.
Key UNCY support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of UNCY market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $7.52 | Sell | $7.45 | Sell |
| MA 10 | $7.88 | Sell | $7.66 | Sell |
| MA 20 | $7.87 | Sell | $7.69 | Sell |
| MA 50 | $7.26 | Sell | $7.38 | Sell |
| MA 100 | $6.90 | Buy | $6.94 | Buy |
| MA 200 | $5.91 | Buy | $6.44 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 40.92 | Neutral |
| Stoch RSI (14) | 0.59 | Buy |
| CCI (20) | -164.23 | Sell |
| Williams %R (14) | -99.33 | Info |
| MACD (12,26,9) | -0.15 | Sell |
| ROC (12) | -10.96 | Sell |
| Bollinger %B (20,2) | 0.01 | Neutral |
| Stochastic %K (14) | 0.67 | Buy |
| TRIX (15) | 0.43 | Buy |
| Awesome (5,34) | -0.03 | Sell |
| Ultimate (7,14,28) | 29.78 | Buy |
| Momentum (10) | -1.10 | Sell |
| Aroon Osc (25) | -28.00 | Sell |
| Hull MA (9) | 7.26 | Sell |
| ADX (14) | 17.98 | Neutral |
| ATR (14) | 0.24 | Info |
The 30-day technical picture is bullish overall, suggesting constructive near-term momentum.
Key trend indicators show an RSI(14) of 40, with the 50-day simple moving average at $7.26 and the 200-day simple moving average at $5.90. These indicators imply a price around a short-term moving average with defined support and resistance nearby.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $5.52 | $7.07 | $12.07 | 0% | Neutral | |
| $8.48 | $11.08 | $15.52 | +57% | Bullish | |
| $9.21 | $12.51 | $18.35 | +77% | Bullish | |
| $10.57 | $14.85 | $22.58 | +110% | Bullish | |
| $10.31 | $14.90 | $23.37 | +111% | Bullish | |
| $10.46 | $15.54 | $25.02 | +120% | Bullish | |
| $11.58 | $17.65 | $29.10 | +150% | Bullish | |
| $14.26 | $22.26 | $37.50 | +215% | Bullish | |
| $17.41 | $27.81 | $47.78 | +293% | Bullish | |
| $17.69 | $28.90 | $50.56 | +309% | Bullish | |
| $23.07 | $41.81 | $78.90 | +491% | Bullish | |
| $42.92 | $93.91 | $197.57 | +12.3x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $5.52 | $7.07 | $8.40 | +0.00% |
| June 2026 | $6.16 | $7.30 | $8.89 | +3.21% |
| July 2026 | $6.08 | $7.28 | $9.03 | -0.20% |
| August 2026 | $6.45 | $7.80 | $9.80 | +7.05% |
| September 2026 | $6.95 | $8.46 | $10.76 | +8.51% |
| October 2026 | $7.03 | $8.62 | $11.07 | +1.83% |
| November 2026 | $7.07 | $8.73 | $11.31 | +1.31% |
| December 2026 | $7.44 | $9.24 | $12.07 | +5.86% |
Click any year to see its month-by-month UNCY forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect UNCY to range from $5.52 to $12.07 through 2026. The $7.07 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The UNCY price prediction for 2027 points to an average of $11.08 (low $8.48, high $15.52) — a potential gain of +57% on today's $7.07. Buyers look set to stay in control over this stretch.
In 2028, UNCY is projected to trade between $9.21 and $18.35, averaging $12.51 — a potential gain of +77% from today's $7.07. That is up +13% on the projected 2027 average. Momentum favours further upside here.
Unicycive Therapeutics, Inc.'s 2029 outlook centres on $14.85, within a $10.57 to $22.58 range. That is up +19% on the projected 2028 average. That marks a +110% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, UNCY could reach as high as $23.37, with a base case around $14.90 and support toward $10.31 — roughly +111% from $7.07. Momentum favours further upside here.
Expect UNCY to range from $10.46 to $25.02 through 2031. The $15.54 average target implies a +120% move from current prices. That is up +4% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The UNCY price prediction for 2032 points to an average of $17.65 (low $11.58, high $29.10) — a potential gain of +150% on today's $7.07. Momentum favours further upside here.
In 2033, UNCY is projected to trade between $14.26 and $37.50, averaging $22.26 — a potential gain of +215% from today's $7.07. That is up +26% on the projected 2032 average. Buyers look set to stay in control over this stretch.
Unicycive Therapeutics, Inc.'s 2034 outlook centres on $27.81, within a $17.41 to $47.78 range. That is up +25% on the projected 2033 average. That marks a +293% change versus current levels. Momentum favours further upside here.
By 2035, UNCY could reach as high as $50.56, with a base case around $28.90 and support toward $17.69 — roughly +309% from $7.07. Buyers look set to stay in control over this stretch.
Expect UNCY to range from $23.07 to $78.90 through 2040. The $41.81 average target implies a +491% move from current prices. That is up +45% on the projected 2035 average. Momentum favours further upside here.
The UNCY price prediction for 2050 points to an average of $93.91 (low $42.92, high $197.57) — a potential gain of +12.3x on today's $7.07. Buyers look set to stay in control over this stretch.
Investing $1,000 in UNCY today (≈ 141.442716 UNCY) could be worth
$13,282.89
+$12,282.89 (+1228%) by 2050 · US Dollar
Based on the average projected UNCY price of $93.91 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in UNCYwould be worth at today's price.
$1,000 invested in UNCY on May 27, 2025 (≈ 169.204742 UNCY) would be worth
$1,196.28
+$196.28 (+19.6%) today · 1.20× · US Dollar
Based on a UNCY entry price of $5.91 vs. today's $7.07.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $7.74 | $913.44 | -8.7% |
| 1 month ago | $7.23 | $977.87 | -2.2% |
| 3 months ago | $6.84 | $1,033.63 | +3.4% |
| 6 months ago | $6.47 | $1,092.74 | +9.3% |
| 1 year ago | $5.91 | $1,196.28 | +19.6% |
| All time (4.9y) ago | $50 | $141.4 | -85.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our UNCY forecast.
Our base-case forecast reaches $14.00 around 2029.
Implied market cap at $14.00: $373.8M
The multi-year forecast points to a strong upside trajectory, with a 2026 min of $5.52, an average of $7.06, and a max of $12.08, for an ROI of 0% and neutral sentiment. From 2027 onward, the average price climbs to $10.95 (2027), $12.30 (2028), $14.51 (2029), and $14.35 (2030), with ROIs of 55.1%, 74.2%, 105.6%, and 103.3% respectively and bullish sentiment.
The forecast continues to rise through 2031–2035, with 2031 avg $14.81, 2032 $16.68, 2033 $20.83, 2034 $26.15, and 2035 $27.12, all accompanied by bullish sentiment and higher potential returns (ROIs 109.8%, 136.3%, 195.1%, 270.4%, 284.2%). By 2040, the average is $38.10 with a max of $72.78 and a 439.7% ROI, still in a bullish frame. By 2050 the forecast shows an average of $85.18 with a max of $181.73 and a 1106.6% ROI, underscoring a continuation of bullish momentum despite inherent uncertainties and market volatility (annualized volatility of 70%).
Tap a question to reveal the answer.
In 2030, the forecasted average price is $14.35, with a min of $9.84 and a max of $22.69, and an ROI of 103.3%. The sentiment is bullish.
The year-by-year forecast shows bullish sentiment in most years after 2026, with rising average prices through 2035 and into 2050 (for example, 2027 avg $10.95; 2050 avg $85.18; 2050 max $181.73; ROI up to 1106.6%). However, 2026 is neutral, and the volatility implied by an annualized volatility of 70% indicates higher risk alongside the upside.
Yes. The modeled path includes a 2050 max of $181.73, which implies the possibility of exceeding $100 under the forecast, while earlier years show lower maximums (e.g., 2040 max $72.78). The forecasted peak in 2050 provides the scenario where $100 is attainable.
The current price is $7.06 and the market cap is $188.5M. The stock is currently ranked 3879 by market cap.
The 30-day technical picture is bullish. RSI(14) is 40; SMA50 is $7.26; SMA200 is $5.90. Key levels are support at $6.90 and resistance at $8.56, with a 30-day price range of $5.48 to $9.10 and an annualized volatility of 70%.
Unicycive Therapeutics, Inc. Community Discussion
0Share your Unicycive Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.